UBS analyst Laura Sutcliffe maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research ...

Jarden analyst Steven Wheen maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research ...

The stock's fall snapped a three-day winning streak.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing ...

ResMed (NYSE:RMD – Get Free Report) is projected to issue its quarterly earnings data after the market closes on Thursday, ...

These stocks have hit new price milestones amid a volatile day for the ASX 200. The post 7 ASX 200 stocks hitting multi-year ...

Shares of ResMed Inc. RMD rose 1.67% to $254.70 Monday, on what proved to be an all-around mixed trading session for the ...

The market expects BellRing Brands (BRBR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story ...

It’s shaping up as a big year for late-stage Australian-listed drug developers, with analysts tipping potentially hefty share ...

ResMed’s stock has surged but faces potential risks from GLP-1 drugs. Find out why RMD stock remains a Hold as investors ...

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.